HUTCHMED (HCM)

Executive Summary

HUTCHMED is a commercial-stage biopharmaceutical company focused on targeted therapies and immunotherapies for oncology and immunology. Its lead drug, fruquintinib, is approved for metastatic colorectal cancer in the U.S., EU, and China, providing a strong revenue base. The company's pipeline includes over 110 drug candidates, with savolitinib (for MET-driven cancers) and sovleplenib (for autoimmune diseases) in late-stage development. HUTCHMED has established commercial capabilities in China and global partnerships with major pharma, supporting a diversified growth strategy. The company's financials benefit from growing product sales and potential milestone payments, positioning it as a key player in the global oncology market.

Upcoming Catalysts (preview)

• Q3 2026Savolitinib NDA Submission in China for MET Exon 14 Skipping NSCLC80% success
• Q4 2026Sovleplenib Phase 3 Data for Primary Immune Thrombocytopenia (ITP)65% success
• 2027Fruquintinib Label Expansion for Endometrial Cancer in China50% success